Dose+

by MVision AI  · Based in Finland → — Automate Smarter, Treat Faster AI-powered platform for Radiotherapy
Oncology Urology

Overview

Dose+ is an AI-powered solution developed by MVision AI Oy, designed to support plan optimization for prostate and pelvic lymph node radiotherapy. Leveraging machine learning techniques, Dose+ generates patient-specific 3D dose predictions from CT images and structure sets, enabling radiation oncology professionals to plan more efficiently and consistently. The software creates clinically achievable VMAT (Volumetric Modulated Arc Therapy) dose distributions, which can be imported into any DICOM-compliant treatment planning system, providing a robust starting point for plan refinement. Dose+ aims to streamline radiotherapy workflows, enhance treatment quality, and reduce manual planning effort, ultimately leading to faster and more patient-focused care.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

  • AI-powered dose prediction for radiotherapy
  • Patient-specific 3D dose estimates
  • Supports plan optimization for prostate and pelvic lymph node radiotherapy
  • Generates clinically achievable VMAT dose distributions
  • Integrates with DICOM-compliant treatment planning systems
  • Reduces manual workload by up to 70%
  • Boosts planning consistency by up to 20%
  • Achieves over 90% clinical acceptance rate
  • Produces predictions in an average of 2 minutes
  • Cloud-based solution with encrypted data transfer

Use Cases

  • Radiotherapy treatment planning for prostate cancer
  • Radiotherapy treatment planning for pelvic lymph node cancer
  • Optimizing inverse planning in radiation therapy
  • Streamlining radiotherapy workflows and increasing efficiency
  • Enhancing treatment quality and consistency across planning scenarios
  • Supporting clinical decision-making in radiation oncology

What Physicians Need to Know

Key Capabilities
Dose+ is an AI-powered solution for radiotherapy planning that generates patient-specific 3D dose predictions from CT images and structure sets. It supports plan optimization for prostate and pelvic lymph node radiotherapy. The system creates clinically achievable VMAT dose distributions and supports all standard fractionation schemes, including simultaneous integrated boost techniques. Dose+ aims to enhance planning consistency, increase efficiency, and provide personalized planning.
Clinical Utility
Dose+ helps radiation oncology professionals plan more efficiently by providing tailored 3D dose estimates that align with clinical best practices. It reduces inter-planner variability and streamlines treatment planning by offering achievable starting points, which can reduce manual adjustments. Clinical validation studies have shown significant efficiency gains in treatment planning while maintaining non-inferior plan quality. It has demonstrated effectiveness across various planning complexities and user experience levels, supporting both automated and manual planning workflows.
Integration Options
Dose+ integrates seamlessly with any DICOM-compliant treatment planning system through a simple DICOM transfer. It is compatible with all major commercial treatment planning systems and requires no local tuning or customization. Dose+ operates as a cloud-based service, with data uploaded through an encrypted connection for processing and then returned to the clinic.
Compliance Status
Dose+ is CE-marked as a Class IIa medical device under MDR and has received FDA 510(k) clearance for clinical use in the United States. It is also GDPR and HIPAA compliant, ensuring data protection and patient privacy through pseudo-anonymization and encrypted data transfer.
Pricing Model
Information regarding the specific pricing model for Dose+ is not publicly available.
User Experience
Dose+ is designed for immediate clinical implementation and improved workflow efficiency, as the models do not require local tuning or adjustments. It reduces human interactions by up to 70% and boasts a clinical acceptance rate of over 90%. The average processing time for dose predictions is approximately 2 minutes. The solution is easy to install and configure, with online and on-premises training available.
Support Quality
MVision AI provides dedicated customer service to quickly resolve any issues. Updates to the Dose+ solution are delivered via the cloud.
Implementation Complexity
Dose+ is described as easy to install and configure, with models that are pre-trained and ready to use, eliminating the need for local data training or extensive setup. It integrates seamlessly into existing clinical workflows.
Evidence Base
Dose+ has been clinically validated across multiple international institutions, demonstrating strong performance across different treatment planning systems. Studies have shown that AI-guided planning leads to more consistent outcomes across different planners and treatment planning systems. A case study at the Northern Centre for Cancer Care (NCCC) in the UK reinforced Dose+ as a clinically valuable tool for efficient, consistent, and high-quality radiotherapy planning in both standard and complex prostate cases. A peer-reviewed paper naming Dose+ was published in September 2026, which was a single-center retrospective comparison with RapidPlan for prostate focal boost, done in collaboration with MVision.
Physician Tip

Dose+ can significantly streamline your radiotherapy planning for prostate and pelvic lymph node cases by providing fast, personalized dose predictions. This can reduce manual workload and inter-planner variability, leading to more consistent and efficient treatment plans. While it offers a strong starting point, remember that all AI-generated dose predictions require review and validation by qualified professionals before clinical use. It's particularly valuable for complex cases, where it can help identify necessary trade-offs early in the planning process.

Dose+ is designed for seamless integration into existing clinical workflows. It is compatible with all DICOM-compliant treatment planning systems and operates as a cloud-based service, transferring data securely via DICOM. This vendor-neutral approach allows for smooth adoption without requiring extensive local tuning or customization.

Details

Category Oncology AI, Pharmacology & Dosing AI
Pricing Unknown
Compliance
BAA AvailableUnknown
HIPAA CompliantUnknown
FDA Status Unknown
Integrations
EHR Not specified
Specialties Oncology, Urology

FDA clearance history

This product’s FDA authorization. From FDA’s list of AI-enabled medical devices; each number links to FDA’s record.

Decision dateNumberName as listed by FDA
2025-09-04K250064 510(k)Dose+

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate Dose+

Clinical Value
Ease of Use
Integration
Support & Docs
Value for Money
No press coverage or publications on file yet. Know of some? Suggest an edit →

Videos

Product demos, reviews, and walkthroughs for Dose+.

View all on YouTube

Frequently Asked Questions

Dose+ is designed for seamless integration into existing clinical workflows. It uses standard DICOM protocols to transfer CT images and structure sets, generating patient-specific 3D dose distributions that can be imported directly into any DICOM-compliant treatment planning system. This vendor-neutral approach ensures compatibility with major commercial treatment planning systems without requiring local tuning or customization.
Dose+ is specifically validated for prostate and pelvic lymph node cases in radiation therapy planning. It features specialized AI models for both prostate and pelvic lymph node radiotherapy, supporting inverse planning for localized prostate cancer and assisting in cases involving lymph nodes.
Dose+ is a software medical device intended for use by qualified radiation therapy professionals. It is CE-marked (Class IIa under MDR) and has received FDA 510(k) clearance for clinical use in the United States. All dose predictions generated by Dose+ require review and validation by qualified professionals before clinical use, as the software serves as a planning aid and is not intended to trigger treatment decisions independently.
Dose+ is a planning aid and does not replace a treatment planning system; its predictions require review and validation by qualified professionals. The software utilizes pre-trained machine learning models that are not modifiable by the end-user. While AI tools like Dose+ offer significant advantages, general limitations of AI in oncology include potential for insufficient accuracy, limited data diversity leading to bias, and challenges in integration into complex clinical workflows.
While Dose+ focuses on patient-specific 3D dose predictions for radiation therapy, other AI tools in oncology offer various functionalities. For example, some AI platforms focus on personalizing chemotherapy dose recommendations based on individual patient data, while others assist with diagnostic support, treatment response prediction, and surgical planning through 3D modeling. The field of AI in oncology is rapidly advancing, with various solutions emerging to optimize different aspects of cancer care.

Related Tools

VERITON CT 400 Series Digital SPECT/CT System (VERITON CT 416/464)
Spectrum Dynamics Medical
Oncology AI
The VERITON CT 400 Series is a digital SPECT/CT system with a 360-degree gantry and 12 swiveling CZT detectors, offering high sensitivity and quantitative accuracy for a wide range of nuclear medicine applications, including advanced theranostics imaging.
syngo.via MI Workflows, syngo MBF
Siemens Medical Solutions USA
Cardiology AI
syngo.via MI Workflows, syngo MBF is an intelligent, integrated imaging software that helps address the challenges of interpreting, managing, and sharing complex data from molecular imaging scanners, providing automated workflows and advanced visualization for various clinical applications.
syngo.via MI WorkFlows, Scenium, syngo MBF
Siemens Medical Solutions USA
Cardiology AI
syngo.via MI Workflows, Scenium, and syngo MBF are medical diagnostic post-processing applications for viewing, manipulation, quantification, analysis, and comparison of PET or nuclear-medicine functional data with CT or MR anatomical data across timepoints, supporting disease management and radiotherapy treatment planning by trained healthcare professionals.
BIOGRAPH One
Siemens Healthineers AG
Oncology AI
BIOGRAPH One is a second-generation PET/MR scanner designed to transform PET/MR image quality for a new era, combining high PET precision with powerful MR performance. It enables simultaneous visualization of organ location, function, and cellular metabolism, offering faster image acquisition times and more efficient workflows than previous generations of PET/MR scanners.
Claire™ OCT System
Perimeter Medical Imaging AI
Oncology AI
Perimeter Medical Imaging AI is a medical technology company driven to transform cancer surgery with ultra-high resolution, real-time, advanced imaging tools that address unmet medical needs.S. for intraoperative breast cancer margin assessment.
syngo.via RT Image Suite VC10
Varian Medical Systems, Inc.
Clinical Decision Support & Reference
syngo.via RT Image Suite VC10 offers advanced imaging and workflow solutions for precise and efficient radiation therapy planning.

See all Oncology AI tools →

More from MVision AI

Contour+ (MVision AI Segmentation)
MVision AI
Oncology AI
Contour+ by MVision AI is an AI-powered auto-segmentation software for radiation therapy, automating the delineation of organs-at-risk and lymph nodes to enhance efficiency, consistency, and patient care.

View company profile →

Suggest an Edit → | Report an issue | Last Verified: 2026-11-10 | First Added: 2026-04-18
AI Tool Finder
AI-powered search. Results may not be comprehensive.